<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2023//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_230101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Curated"><PMID Version="1">34110677</PMID><DateCompleted><Year>2021</Year><Month>08</Month><Day>13</Day></DateCompleted><DateRevised><Year>2022</Year><Month>05</Month><Day>31</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1468-1331</ISSN><JournalIssue CitedMedium="Internet"><Volume>28</Volume><Issue>8</Issue><PubDate><Year>2021</Year><Month>Aug</Month></PubDate></JournalIssue><Title>European journal of neurology</Title><ISOAbbreviation>Eur J Neurol</ISOAbbreviation></Journal><ArticleTitle>Familial clustering of primary lateral sclerosis and amyotrophic lateral sclerosis: Supplementary evidence for a continuum.</ArticleTitle><Pagination><StartPage>2780</StartPage><EndPage>2783</EndPage><MedlinePgn>2780-2783</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1111/ene.14960</ELocationID><Abstract><AbstractText Label="BACKGROUND AND PURPOSE">Primary lateral sclerosis (PLS) is a motor neuron disorder characterized by a pure upper motor neuron degeneration in the bulbar and spinal regions. The key difference with amyotrophic lateral sclerosis (ALS) is the lower motor neuron system integrity. Despite important literature on this disease, the pathophysiology of PLS remains unknown, and the link with ALS still balances between a continuum and a separate entity from ALS.</AbstractText><AbstractText Label="METHODS">We report nine families in which both PLS and ALS cases occurred, in general among first-degree relatives.</AbstractText><AbstractText Label="RESULTS">The patients with PLS and ALS had a typical disease presentation. Genetic studies revealed mutations in SQSMT1, TBK1, and TREM2 genes in two PLS patients and one ALS patient.</AbstractText><AbstractText Label="CONCLUSIONS">These results strongly support a phenotypic continuum between PLS and ALS.</AbstractText><CopyrightInformation>&#xa9; 2021 European Academy of Neurology.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Corcia</LastName><ForeName>Philippe</ForeName><Initials>P</Initials><Identifier Source="ORCID">0000-0002-1625-8845</Identifier><AffiliationInfo><Affiliation>ALS Center, CHU Bretonneau Tours, Tours, France.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>UMR 1253 iBrain, Universit&#xe9; de Tours, Inserm, Tours, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Lunetta</LastName><ForeName>Christian</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>NEMO Clinical Center, Serena Onlus Foundation, Milan, Italy.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>NEMO Lab, Milan, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Couratier</LastName><ForeName>Philippe</ForeName><Initials>P</Initials><AffiliationInfo><Affiliation>ALS Center, CHU Dupuyten, Limoges, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Vourc'h</LastName><ForeName>Patrick</ForeName><Initials>P</Initials><AffiliationInfo><Affiliation>UMR 1253 iBrain, Universit&#xe9; de Tours, Inserm, Tours, France.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Biochemistry, Molecular Biology, CHU Tours, Tours, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Gromicho</LastName><ForeName>Marta</ForeName><Initials>M</Initials><Identifier Source="ORCID">0000-0003-2111-4579</Identifier><AffiliationInfo><Affiliation>Faculty of Medicine, Instituto de Fisiologia, Instituto de Medicina Molecular, Universidade de Lisboa, Lisbon, Portugal.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Desnuelle</LastName><ForeName>Claude</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>ALS Center, CHU Nice, H&#xf4;pital Pasteur 2, Nice, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Soriani</LastName><ForeName>Marie-H&#xe9;l&#xe8;ne</ForeName><Initials>MH</Initials><AffiliationInfo><Affiliation>ALS Center, CHU Nice, H&#xf4;pital Pasteur 2, Nice, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Pinto</LastName><ForeName>Susana</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Faculty of Medicine, Instituto de Fisiologia, Instituto de Medicina Molecular, Universidade de Lisboa, Lisbon, Portugal.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>de Carvalho</LastName><ForeName>Mamede</ForeName><Initials>M</Initials><Identifier Source="ORCID">0000-0001-7556-0158</Identifier><AffiliationInfo><Affiliation>Faculty of Medicine, Instituto de Fisiologia, Instituto de Medicina Molecular, Universidade de Lisboa, Lisbon, Portugal.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Neurosciences and Mental Health, Hospital de Santa Maria-Centro Hospitalar Universit&#xe1;rio Lisboa Norte, Lisbon, Portugal.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2021</Year><Month>06</Month><Day>23</Day></ArticleDate></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>Eur J Neurol</MedlineTA><NlmUniqueID>9506311</NlmUniqueID><ISSNLinking>1351-5101</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D008562">Membrane Glycoproteins</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D011971">Receptors, Immunologic</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C099718">SQSTM1 protein, human</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000071456">Sequestosome-1 Protein</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C498715">TREM2 protein, human</NameOfSubstance></Chemical><Chemical><RegistryNumber>EC 2.7.11.1</RegistryNumber><NameOfSubstance UI="D017346">Protein Serine-Threonine Kinases</NameOfSubstance></Chemical><Chemical><RegistryNumber>EC 2.7.11.1</RegistryNumber><NameOfSubstance UI="C403191">TBK1 protein, human</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><CommentsCorrectionsList><CommentsCorrections RefType="CommentIn"><RefSource>Eur J Neurol. 2021 Dec;28(12):3875-3876</RefSource><PMID Version="1">34339556</PMID></CommentsCorrections><CommentsCorrections RefType="CommentIn"><RefSource>Eur J Neurol. 2022 Jan;29(1):e3-e4</RefSource><PMID Version="1">34624147</PMID></CommentsCorrections><CommentsCorrections RefType="CommentIn"><RefSource>Eur J Neurol. 2022 Jan;29(1):e1-e2</RefSource><PMID Version="1">34694663</PMID></CommentsCorrections></CommentsCorrectionsList><MeshHeadingList><MeshHeading><DescriptorName UI="D000690" MajorTopicYN="Y">Amyotrophic Lateral Sclerosis</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016000" MajorTopicYN="N">Cluster Analysis</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008562" MajorTopicYN="N">Membrane Glycoproteins</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016472" MajorTopicYN="Y">Motor Neuron Disease</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D009046" MajorTopicYN="N">Motor Neurons</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D017346" MajorTopicYN="N">Protein Serine-Threonine Kinases</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011971" MajorTopicYN="N">Receptors, Immunologic</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000071456" MajorTopicYN="N">Sequestosome-1 Protein</DescriptorName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">amyotrophic lateral sclerosis</Keyword><Keyword MajorTopicYN="N">familial clustering</Keyword><Keyword MajorTopicYN="N">genetics</Keyword><Keyword MajorTopicYN="N">phenotype</Keyword><Keyword MajorTopicYN="N">primary lateral sclerosis</Keyword></KeywordList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="revised"><Year>2021</Year><Month>5</Month><Day>22</Day></PubMedPubDate><PubMedPubDate PubStatus="received"><Year>2021</Year><Month>4</Month><Day>19</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2021</Year><Month>5</Month><Day>27</Day></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2021</Year><Month>6</Month><Day>11</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2021</Year><Month>8</Month><Day>14</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2021</Year><Month>6</Month><Day>10</Day><Hour>12</Hour><Minute>39</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">34110677</ArticleId><ArticleId IdType="doi">10.1111/ene.14960</ArticleId></ArticleIdList><ReferenceList><Title>REFERENCES</Title><Reference><Citation>Turner MR, Barohn RJ, Corcia P, et al. Primary lateral sclerosis: consensus diagnostic criteria. J Neurol Neurosurg Psychiatry. 2020;91:373-377.</Citation></Reference><Reference><Citation>De Carvalho M, Kiernan MC, Pullman SL, Rezania K, Turner MR, Simmons Z. Neurophysiological features of primary lateral sclerosis. Amyotroph Lateral Scler Frontotemporal Degener. 2020;21(sup1):11-17.</Citation></Reference><Reference><Citation>Almeida V, de Carvalho M, Scotto M, et al. Primary lateral sclerosis: predicting functional outcome. Amyotroph Lateral Scler Frontotemporal Degener. 2013;14:141-145.</Citation></Reference><Reference><Citation>Le Forestier N, Maisonobe T, Piquard A, et al. Does primary lateral sclerosis exist? A study of 20 patients and a review of the literature. Brain. 2001;124:1989-1999.</Citation></Reference><Reference><Citation>Pringle CE, Hudson AJ, Munoz DG, Kiernan JA, Brown WF, Ebers GC. Primary lateral sclerosis: clinical features, neuropathology and diagnostic criteria. Brain. 1992;115:495-520.</Citation></Reference><Reference><Citation>Appelbaum JS, Roos RP, Salazar-Grueso EF, et al. Intrafamilial heterogeneity in hereditary motor neuron disease. Neurology. 1992;42:1488-1492.</Citation></Reference><Reference><Citation>Brugman F, Wokke JHJ, Vianney de Jong JMB, Franssen H, Faber CG, Van den Berg LH. Primary lateral sclerosis as a phenotypic manifestation of familial ALS. Neurology. 2005;64:1778-1779.</Citation></Reference><Reference><Citation>Praline J, Guennoc AM, Vourc'h P, De Toffol B, Corcia P. Primary lateral sclerosis may occur within familial amyotrophic lateral sclerosis pedigrees. Amyotroph Lateral Scler. 2010;11:154-156.</Citation></Reference><Reference><Citation>Antunes A, Pinto S, Almeida V, Ohana B, de Carvahlo M. Heterogeneity in familial motor neuron disease. J Neurol. 2011;258(Suppl 1):S295.</Citation></Reference><Reference><Citation>Costa MR, Gromicho M, Pronto-Laborinho AC, Miltenberger Milt&#xe9;nyi G, de Carvalho M. Novel TBK1 LoF variant in a family with upper motor neuron predominant motor neuron disease. J Neurol Sci. 2019;403:117.</Citation></Reference><Reference><Citation>Hirsch-Reinshagen V, Alfaify OA, Hsiung GY, et al. Clinicopathologic correlations in a family with a TBK1 mutation presenting as primary progressive aphasia and primary lateral sclerosis. Amyotroph Lateral Scler Frontotemporal Degener. 2019;20:568-575.</Citation></Reference><Reference><Citation>Gazulla J, Ferrer I, Izquierdo-Alvarez S, et al. Hereditary primary lateral sclerosis and progressive non-fluent aphasia. J Neurol. 2019;266:1079-1090.</Citation></Reference><Reference><Citation>Corcia P, Vourc'h P, Blasco H, et al. Phenotypic and genotypic studies of ALS cases in ALS-SMA families. Amyotroph Lateral Scler Frontotemporal Degener. 2018;19:432-437.</Citation></Reference><Reference><Citation>Mackenzie IR, Briemberg H. TDP-43 pathology in primary lateral sclerosis. Amyotroph Lateral Scler Frontotemporal Degener. 2020;21(sup1):52-58.</Citation></Reference><Reference><Citation>Richards S, Aziz N, Bale S, et al. Standards and guidelines for the interpretation of sequence variants: a joint consensus recommendation of the American College of Medical Genetics and Genomics and the Association for Molecular Pathology. Genet Med. 2015;17:405-424.</Citation></Reference><Reference><Citation>Turner MR, Talbot K. Primary lateral sclerosis: diagnosis and management. Pract Neurol. 2020;20:262-269.</Citation></Reference><Reference><Citation>Hardiman O, Al-Chalabi A, Chio A, et al. Amyotrophic lateral sclerosis. Nat Rev Dis Primers. 2017;5(3):17071. https://doi.org/10.1038/nrdp.2017.71</Citation></Reference><Reference><Citation>Mitsumoto H, Nagy P, Gennings C, et al. Phenotypic and molecular analyses of primary lateral sclerosis. Neurol Genet. 2015;1(1):e3. https://doi.org/10.1212/01</Citation></Reference><Reference><Citation>Silani V, Corcia P, Harms MB, Rouleau G, Siddique T, Ticozzi N. Genetics of primary lateral sclerosis. Amyotroph Lateral Scler Frontotemporal Degener. 2020;21(sup1):28-34.</Citation></Reference></ReferenceList></PubmedData></PubmedArticle></PubmedArticleSet>